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Abstract
Despite advances in neonatal and surgical care, the management of congenital diaphrag‐
matic hernia (CDH) remains challenging with no definitive standard treatment guide‐
lines. Several centers report mortality rates as low as 20%, but if extracorporeal membrane 
oxygenation (ECMO) support is required, the mortality rate rises to 50%. The disease 
severity is related to the degree of pulmonary hypoplasia and pulmonary hypertension 
that occurs with CDH. Both conditions decrease the infant’s ability to ventilate and oxy‐
genate adequately at delivery. These physiologic conditions that impair gas exchange 
are the important determinants of morbidity and mortality in CDH infants. Presently, 
delivery of infants with CDH is recommended close to term gestation. The focus of care 
includes gentle ventilation, hemodynamic monitoring, and treatment of pulmonary 
hypertension followed by surgery for the defect. Extracorporeal membrane oxygenation 
(ECMO) is considered after failure of conventional medical management for infants ≥  34 
weeks’ gestation or with weight >2 kg and no associated major lethal anomalies. This 
chapter discusses long‐term follow‐up recommendations for survivors, which should 
involve a multidisciplinary approach, as there are many surgical and nonsurgical conse‐
quences to the disease process. Clinical strategies that address these multifaceted aspects 
of care, from prenatal to long‐term follow‐up, may further reduce the high mortality rate 
for these infants.
Keywords: respiratory failure, pulmonary hypertension, pulmonary hypoplasia, extra‐
corporeal membrane oxygenation
1. Introduction
A congenital diaphragmatic hernia (CDH) is a developmental defect of the posterior lateral 
part of the diaphragm. The opening allows the abdominal organs to slide into the chest or 
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“herniate” which may lead to underdevelopment of the lungs. The lung on the ipsilateral side 
of the hernia is generally smaller.
CDH is six times more common on the left than the right. The incidence is reported between 
one in 2200 and one in 3500 live births. Rare bilateral defects are generally fatal. The differ‐
ential diagnosis includes congenital pulmonary airway malformation (CPAM), bronchogenic 
cyst, and eventration [1].
Despite advances in neonatal and surgical care, the management of CDH remains challeng‐
ing with no definitive standard treatment guidelines. The mortality rate is high, with little 
change over the past few decades, and is generally reported between 30 and 45%. Several cen‐
ters report mortality rates as low as 20%. If extracorporeal membrane oxygenation (ECMO) 
support is required, the mortality rate rises to 50% [2].
The severity of the disease is related to the degree of pulmonary hypoplasia and pulmonary 
hypertension that occurs with CDH. Both conditions decrease the infant’s ability to ventilate 
and oxygenate adequately at delivery. These physiologic conditions that impair gas exchange 
are the important determinants of morbidity and mortality in CDH infants.
2. Embryology
Incomplete fusion of embryologic elements that give rise to the diaphragm leads to the hernia 
defect. CDH occurs at distinct sites. Ninety percent are a posterolateral defect (Bochdalek hernia) 
and 9% are an anterolateral defect (Morgagni hernia). Total agenesis may occur.
3. Inheritance patterns
Congenital diaphragmatic hernia generally presents sporadically. The CDH risk in a sibling 
is less than 2%, due to multifactorial patterns of inheritance [3]. There are rare incidences of 
dominant and X‐linked recessive inheritance for isolated defects [4]. Bilateral lesions tend 
to familial inheritance and bilateralism, and tend to have less severe associated anomalies. 
Familial diaphragmatic agenesis, however, is an autosomal recessive syndrome, is a distinct 
syndrome with a worse prognosis than posterolateral diaphragmatic hernia [5].
There are no firmly established teratogens associated with CDH. Diaphragmatic hernia is 
associated with Fryn’s syndrome [6], Beckwith‐Wiedemann syndrome [7], and Pierre Robin 
syndrome [8].
4. Associated anomalies
Most fetuses with severe associated anomalies die in utero. Therefore, the incidence of pre‐
natal abnormalities is higher than that reported in the literature by pediatric surgeons and 
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lower than postmortem studies. In prenatal series, only about 50% of fetuses have an isolated 
diaphragmatic defect. In about 25% of cases, there is a chromosomal abnormality, usually 
Trisomy 21, trisomy 18 or 13, which is similar to omphalocele infants [9]. In another 25%, there 
is a major defect including cardiovascular defects atrial septal defect (ASD), ventricular septal 
defect (VSD), hypoplastic left heart, tetralogy of Fallot, transposition). The overall survival of 
infants with CDH and a chromosomal anomaly is poor.
4.1. Prenatal evaluation
Ultrasound screening examination in the prenatal period will generally diagnose a congenital 
diaphragmatic hernia. Prenatal evaluation of CDH is important for parental counseling, prognos‐
tication, and postnatal management. The prenatal evaluation of the postnatal prognosis of CDH 
is improving, but better standardization of evaluation methods is needed to compare results.
The prenatal ultrasound diagnosis is based on the following factors:
1. The presence of abdominal organs visualized within the thoracic cavity. Ultrasound may reveal 
a left‐sided CDH if the stomach or loops of bowel are partially or totally within the thorax.
2. The heart position may shift, or cardiac compression may be observed, from the organs in 
the thoracic cavity.
3. Polyhydramnios is common, either due to esophageal compression or reduced absorption of 
fluid by the hypoplastic lungs, but it is rarely observed before 24‐week gestation.
Any mediastinal shift or hydrothorax, abnormal position of the gallbladder, hepatic veins, or 
even umbilical veins should arouse suspicion of a right‐sided hernia. It may be a challenging 
diagnosis because the lungs and liver have similar echogenicity.
At antenatal diagnosis, the following studies and consultations are recommended:
1. chromosomal analysis
2. serial prenatal ultrasound examinations
3. a fetal echocardiograph
4. pediatric surgery consultation
These investigations are relevant, even in the third trimester of pregnancy, because knowledge 
that the fetus is chromosomally and otherwise structurally normal allows the parents, obstetri‐
cian, pediatrician, and surgeon to discuss the mode, place, and timing of delivery.
Prognosis: The primary determinants of survival for infants with CDH are the presence of 
associated anomalies, pulmonary hypoplasia, and pulmonary hypertension. Prenatally dis‐
covered cases and cases diagnosed before 24‐week gestation have a worse prognosis because 
of the early stage of the lung development when the anomaly has occurred. Mortality in this 
group is reported as high as 60–80% [10].
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4.2. Pulmonary hypoplasia
Pulmonary hypoplasia occurs in CDH and is the main cause of mortality. Pulmonary hypo‐
plasia is defined as incomplete development of the lungs with decreased bronchopulmo‐
nary segments and diminished alveolar septation [11]. Incomplete development results in a 
decreased total lung volume.
Much prenatal investigation is directed toward the accurate evaluation of pulmonary hypo‐
plasia. Its antenatal prediction remains one of the challenges of prenatal diagnosticians. 
Accurate case selection identifies those cases that may benefit from prenatal surgery.
Fetuses with CDH and a “poor prognosis” with postnatal treatment have
• a low lung‐to‐head ratio (LHR) on ultrasound
• a diagnosis before 25‐week gestation
• liver herniation on prenatal ultrasound
• a fetal magnetic resonance imaging (MRI) consistent with a low lung volume.
4.3. Lung to head ratio
The lung‐head ratio (LHR) is calculated by 2D ultrasound. For accurate prognostication, the 
measure must be performed between 22 and 28‐week gestation. The length and width of the 
right lung is measured and multiplied to calculate the right lung area. The right lung area is 
then divided by the head perimeter measure Figure 1.
For example:
• Right lung area: 21 mm × 10 mm = 210 mm2
• Head perimeter: 200 mm
Lung‐to‐head ratio (LHR): 210/200 = 1.05
A lung‐to‐head ratio of 1.0 or less has a poor prognosis, despite ECMO. If the ratio is greater 
than 1.4, the prognosis is much better. Lung‐to‐head ratios between 1.0 and 1.4 have about a 
38% survival rate. Most cases with an LHR in this range require ECMO. Overall, survivors 
have a mean lung‐to‐head ratio in the range of 1.4 ± 0.33 and nonsurvivors, 1.05 ± 0.3 [12].
The presence of liver in the chest on prenatal ultrasound is a poor prognosticator for survival 
[13, 14].
A recent meta‐analysis analyzed the ability of lung‐to‐head ratio (LHR), observed‐to‐expected 
LHR (o/e LHR), total fetal lung volume (TFLV), o/e TFLV, percentage predicted lung volume 
(PPLV), and degree of liver herniation to predict neonatal morbidity and mortality in fetuses 
with CDH.
The primary outcome was perinatal survival and the secondary outcome was the use of extra‐
corporeal membrane oxygenation (ECMO).
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Twenty‐two articles published before April 2016 met the inclusion criteria.
The odds of survival with LHR <1.0 was 0.14 (CI: 0.10–0.27) and with liver herniation on ultra‐
sound it was 0.21 (CI: 0.13–0.35).
The O/E LHR and O/E TFLV performed best in this prediction model. The most discrimina‐
tory threshold for lung volume and mortality was O/E LHR <1 and for O/E TFLV, it was 25%. 
LHR <1 was predictive of extracorporeal life support (ECLS) use. Overall, the O/E LHR <1, O/E 
TFLV (thresholds of 25%), and liver herniation are good predictors of mortality in CDH [13].
Similarly, Partridge reports that serial lung to head growth measures are a better prognosticator 
for lung growth and survival. Of 226 CDH infants identified over 10 years, 72 died (32%). Liver 
in the chest or use of patch for closure of the defect were associated with mortality. The rate of 
lung to head ratio increase, as measured by linear regression and slope analysis, was signifi‐
cantly better in survivors [15].
4.4. Fetal MRI consistent with a low lung volume
Fetal magnetic resonance imaging (MRI) has undergone major technical improvement since 
it was first performed over 30 years ago. It complements US studies by providing better 
Figure 1. Calculation of lung: head ratio from 2D ultrasound. (From: 2000‐05‐29‐17 Diaphragmatic hernia © Novakov 
www.thefetus.net).
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visualization when ultrasound is limited by oligohydramnios or maternal obesity. Other 
advantages include a larger field of view and better tissue contrast than US. It is not limited 
by shadowing from osseous structures. However, the limitations include a decreased resolu‐
tion compared with US, less availability, and increased cost.
Multiple MRI studies have reported normal fetal lung volumes based on gestational age. In 
cases of CDH, the risk for pulmonary hypoplasia can be assessed by comparing the lung volume 
measured by MRI with a normal value for the gestational age; however, the literature results 
have been inconsistent and have not reliably predicted outcome. There is a lack of standardiza‐
tion of MRI technique in the literature.
A curve of normal fetal lung volume values plotted against gestational age has been established 
and validated for fetal MRI [16]. The observed/expected total fetal lung volume (O/E‐TFLV) 
ratio is calculated by dividing the measured fetal lung volume by the expected mean fetal lung 
volume for a given gestational age [16].
The fetal MRI planimetric measurements of ipsilateral, contralateral, and total fetal lung 
volume (TFLV) are performed with T(2)‐haste sequences in transverse, coronal, and sagittal 
planes. All values are expressed as a ratio of what was observed over what is expected for a 
gestation age matched normal fetus.
One study reports the measurement of O/E LHR on ultrasound allowing a reasonable esti‐
mation and correlation of O/E contralateral FLV as well as TFLV as measured by MRI [17]. 
Additional parameters such as gestational age, liver position, and side of defect improved the 
estimation of TFLV.
Others report that lung size and liver herniation predict the need for ECMO but do not predict 
pulmonary hypertension [18].
A review of articles that provided normal fetal lung volumes for gestational age revealed 
much variability in absolute lung volume within each individual study. Each study had a 
solitary reporter. The best‐fit curves ranged from 20 to 35 ml at 25 weeks’ gestation and 58 to 
95 ml at 35 weeks’ gestation [19]. The study by Rypens et al. included the largest number of 
fetuses and, in contrast, included measurements by several observers at different institutions 
[16]. The ability of MRI to predict prognosis and survival for CDH is inconsistent, although 
multiple studies have shown a correlation between fetal lung volume in CDH and postnatal 
outcomes of neonatal survival and ECMO.
Infants with CDH generally have O/E‐TFLV measurements ranging from 25 to 45% or lower. They 
require more pulmonary support than omphalocele and congenital lung malformation infants. 
Clinical‐radiologic correlation studies support the use of prenatal MRI to predict perinatal and 
postnatal outcomes. The measurements may guide fetal therapy with improved postnatal results. 
An O/E TFLV below 35% is associated with increased ECMO use and a higher mortality [20].
One review of articles encompassing 269 fetuses with congenital diaphragmatic hernia reported 
areas under the receiver operating characteristic (ROC) curves ranging from 0.786 to 0.900 in 
the prediction of survival. Two others involving MRI‐measured fetal lung volume reported 
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the area under the ROC curves to range from 0.653 to 0.770 in the prediction of extracorporeal 
membrane oxygenation requirement. All of the above studies utilized MR measurements of 
fetal lung volume compared with normal lung volume data from either the Rypens et al. study 
or formulas based on gestational age or biometric parameters [19].
Further studies are needed to assess and develop the full potential of MRI measurement of 
fetal lung volume in predicting neonatal prognosis.
4.5. Prenatal surgery
If LHR is <1, LHR 0/E is less than 25%, or liver is in the thorax, survival for CDH infants is less 
than 25%. In these fetuses, in utero treatments are sometimes offered such as fetal endotra‐
cheal occlusion (FETO) [10, 21].
Many experimental models of in utero surgery for CDH exist. Prenatal treatment of the fetus 
has been proposed to avoid pulmonary hypoplasia. However, a hysterotomy is required. The 
subsequent caesarian section on an otherwise healthy mother has significant morbidity and 
risk of premature labor.
Open fetal surgery, while feasible, does not improve survival over standard postnatal treat‐
ment in the subgroup of congenital diaphragmatic hernia fetuses without liver herniation. 
The data from this randomized trial suggest that fetuses with a prenatally diagnosed CDH 
without evidence of liver herniation should be treated postnatally [10].
Fetal endotracheal occlusion (FETO) is thought to prevent outward movement of pulmonary 
fluid. The retention of lung fluid may improve lung expansion and even possibly promote 
reduction of the viscera into the peritoneal cavity [21]. The placement of a “tracheal clip” 
may accelerate lung growth and avoid the development of fatal pulmonary hypoplasia [22]. 
Endoscopic techniques decrease the risk of preterm labor and other complications of open 
fetal surgery.
The best candidates for this procedure are fetuses with a left CDH, liver herniation, and a low 
lung‐to‐head ratio that are at high risk of neonatal demise [23]. A minimally invasive intra‐
luminal tracheal occlusion technique, which avoids laparotomy, hysterotomy, and fetal neck 
dissection, has been recently accomplished. This technique may change the surgical approach 
to the fetus with severe CDH [24].
In 2017, 20 fetuses with CDH, an LHR<1 and liver herniation were reviewed [24]. Nine were 
managed without tracheal balloon occlusion; tracheal occlusion was offered in 11 and in 10, 
it was successful. The mean gestational age at FETO was 27.9 (1.1) weeks. The occlusion was 
reversed at 34 weeks and the infants were delivered at 35 weeks. One required an EXIT proce‐
dure to remove the balloon. All underwent postnatal repair of CDH with patch. The 6‐month, 
1‐year, and 2‐year survival were significantly higher in the treated than nontreated cohort. 
They concluded that FETO is feasible and associated with improved postnatal outcomes in 
severe Left CDH infants. A large multicenter randomized trial is still needed to demonstrate 
the real benefits of FETO [25].
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5. Pulmonary hypertension
The developing lung is subject to genetic, pathological, and environmental influences that 
affect lung adaptation, development, and growth.
Neonates with CDH are primarily classified as having vascular hypoplasia, yet lung histology 
of fatal cases typically shows marked muscularization of pulmonary arteries, and clinically, 
these patients frequently respond to vasodilator therapy.
An early developmental arrest in the normal pattern of airway branching in both lungs, 
resulting in reduced lung volume and impaired alveolarization, will present as a severely 
symptomatic CDH after birth [26].
This arrest may occur in pulmonary arterial branching and result in a reduced cross‐sectional 
area of the vascular bed, thickened media, and adventitia of small arterioles, and abnormal 
medial muscular hypertrophy that extends distally to the acinar arterioles. Although in utero 
lung compression by herniated viscera may be the primary mechanism of the lung abnormali‐
ties of CDH, decreased pulmonary blood flow alone may cause lung hypoplasia [27].
After birth, pulmonary vascular resistance (PVR) often remains at suprasystemic levels. This 
increased pulmonary right‐to‐left shunting across the foramen ovale and ductus arteriosus 
manifests in the infant as profound hypoxemia. High PVR is related to multiple factors, 
including the small cross‐sectional area of pulmonary arteries, structural vascular remodel‐
ing, vasoconstriction with altered reactivity, and left ventricular dysfunction. The mediators 
of altered pulmonary vascular reactivity in CDH are not well understood, although much 
evidence points to disruptions in nitric oxide (NO), cyclic guanosine monophosphate (GMP) 
and endothelin signaling [28].
The pathophysiology of hypoxemia in CDH is also related to abnormalities of cardiac develop‐
ment and function. The left ventricle, left atrium, and intraventricular septum are hypoplastic in 
infants that die of CDH relative to age‐matched controls, perhaps from low fetal and postnatal 
pulmonary blood flow and/or compression by the dilated right ventricle [28].
CDH is also associated with increased resistance of the pulmonary vasculature. Pulmonary hyper‐
tension (PHN) is characterized by elevated pulmonary vascular resistance, resulting in right to 
left shunting and hypoxemia. Differential hypoxemia is observed between the preductal‐ and 
postductal saturation monitors. Pulmonary hypertension is confirmed and monitored by serial 
echocardiography. Studies that aim to diagnose impaired vascular development are needed.
Yamoto et al. investigated the prenatal echocardiography factors that relate to outcomes in left‐
sided CDH [29]. Data were collected between 2006 and 2010. Severe cardiac anomalies and chro‐
mosomal anomalies were excluded. Of 84 patients, 8 died before 90 days (9.5%). Initial analysis 
revealed that the postnatal echo predictors of poor outcome were continuous right to left shunt‐
ing, left pulmonary artery diameter of <2.7 mm, a right pulmonary artery diameter of <3.3 mm, 
and a left ventricular diameter of <10.8 mm. Logistic regression analysis found a small right 
pulmonary diameter and a smaller left ventricular diastolic diameter that were independently 
associated with poor outcomes. However, the postnatal echo was sometimes performed within 
24 hours after birth, during the time of transitional circulation, and is a limitation of this study.
Hernia160
The optimal management of the structural and functional changes in the heart, pulmonary 
vasculature, airways, and lung parenchyma is challenging. The treatment of PHN in infants 
with CDH evolves and changes as the underlying pathophysiology evolve in the days and 
weeks after birth. Unlike other diseases resulting in persistent pulmonary hypertension of the 
newborn, infants with CDH are often refractory to inhaled nitric oxide (iNO). Nitric oxide 
mediates pulmonary vasodilatation at birth in part via cyclic GMP production. Evidence sug‐
gests several disorders exist in CDH infants (e.g., surfactant deficiency, decreased antioxidant 
activity, increased vascular reactivity with decreased nitric oxide and increased endothelin 1 
activity, and left heart hypoplasia) which may be associated with impaired lung development. 
It is unclear at present how nitric oxide, sildenafil, and bosentan will modulate pulmonary 
hypertension in CDH infants. Chronic pulmonary hypertension can persist into childhood 
and may contribute to late mortality [26].
6. Postnatal management
It is recommended that CDH infants are delivered as close to 39 weeks as possible. Neuromuscular 
blockade is avoided in the delivery room. The preductal saturation is kept between 80 and 95%, 
and the postductal at greater than 70%. The target pCO
2
 is 50–70 mmHg on conventional ven‐
tilation. Intravenous sildenafil should be administered in the presence of severe pulmonary 
hypertension.
6.1. Immediate postnatal resuscitation and medical management
In fetuses known antenatal to have CDH, the aim of resuscitation at birth is to obtain car‐
diopulmonary stability, and interrupt the progression to hypercapnia, hypoxemia, acidosis, 
and worsening PHN. Infants are intubated, and mechanically ventilated. The initial ventila‐
tion mode is conventional mandatory ventilation (CMV). High frequency oscillatory venti‐
lation (HFOV) is initiated when criteria for transition from conventional to HFOV are met. 
HFOV offers more invasive ventilation support, while minimizing barotrauma to the lungs. 
Cardiovascular support to avert PHN is needed. ECMO is reserved for patients with severe 
pulmonary or cardiac compromise refractory to medical management.
Carbon dioxide level and subsequent management can provide predictive information 
regarding the outcome of CDH. The initial CO
2
 is significantly higher and PaO
2
 is lower in 
30‐day mortalities than in survivors. Infants who remain hypercarbic after resuscitation also 
have a worse prognosis. PaCO
2
 levels are a biomarker of successful management. The best 
oxygen index on the first day of life has been shown to predict outcome. Park et al. reported 
the PaO
2
 and PaCO
2
 from the first blood gas after birth predicted the need for ECMO and 
mortality [30].
Initial management includes nasogastric decompression, central venous access, total paren‐
teral nutrition, and careful fluid management to optimize cardiopulmonary stability. Frequent 
echocardiography is required to identify structural cardiac anomalies and assess function and 
response to therapy [31].
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6.2. Score for neonatal acute physiology (SNAP score)
Predictive outcome models are essential for outcome analysis of CDH. The ideal equation 
should generalize across CDH datasets. Existing mortality‐predictive models include those of 
the CDH study group (CDHSG) based on birth weight and 5‐minute Apgar score, the score 
for Neonatal Acute Physiology version II, and the Wilford Hall/Santa Rosa clinical prediction 
formula (WHSR(PF)) derived from blood gas measurements. The score for neonatal acute 
physiology (SNAP 2) score is one of the most applicable scoring systems for CDH infants.
The CDH EURO consortium expanded the implications of the SNAP score first published 
by Skarsgard et al. [32]. A prospective randomized study of 11 centers that participate in the 
CDH EURO consortium was undertaken [33]. Data were collected between 2008 and 2013 
(SNAP 2). High volume centers were included and were defined as centers that treat at least 
10 CDH infants per year. Infants with prematurity below 34 weeks were excluded, so those 
with premature lung physiology would not influence results.
The exclusion criteria were gestation below 34 weeks, severe chromosomal anomalies, severe 
cardiac anomalies with need for operation within 60 days, renal anomalies associated with oli‐
gohydramnios, and severe orthopedic, skeletal, and central nervous system (CNS) anomalies. 
All infants were inborn. The out‐born infants were excluded because out‐born survivors tend 
to have less severe disease and therefore contribute bias to the results.
The aims of the SNAP 2 study were to prospectively evaluate whether SNAP 2 predicted mor‐
tality, the need for ECMO or bronchopulmonary dysplasia (BPD) development.
All infants were randomized to a standard protocol of CMV or HFOV.
The SNAP 2 was collected in the first 12 hours of life and included the worst score of each of 
the following data points: mean blood pressure, temperature, PaO
2
, inspired oxygen concen‐
tration (fi02), serum pH, the presence of multiple seizures, and the lowest urine output.
Infants met the criteria for ECMO if they met the following failure criteria for 3 hours: inabil‐
ity to maintain a preductal saturation above 85%, or a postductal saturation above 70%, an 
increase in CO
2
 of greater than 65 mmHg, a peak inspiratory pressure of greater than 28 cm of 
H
2
O, inadequate O
2
 delivery with metabolic acidosis defined as pH < 7.2 or an oxygen index 
consistently greater than 40.
Of 171 infants, 46 died (27.0%). Of 108 treated at ECMO centers, 40 received ECMO (37.0%) 
and 27 died (25%). Of those treated in 63 centers without ECMO, 19 died (30.0%). The differ‐
ence in mortality rate between ECMO and nonECMO centers was not significant (p = 0.46). Of 
125 survivors, 39 developed BDP (31.2%).
In nonsurvivors, the median SNAP 2 was 42.5, and in survivors it was 16.5, a significant differ‐
ence (p < 0.001). Of 108 born in ECMO centers, the median SNAP 2 was 35 in those treated with 
ECMO and 16 in those that did not undergo ECMO, also a significant difference (p < 0.001). 
The median SNAP 2 was also significantly different for ECMO survivors and nonsurvivors: 
32 vs. 40, p = 0.04. Logistic regression and ROC analysis showed the SNAP 2 was significantly 
associated with mortality, need for ECMO and BPD.
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This large study of prenatally detected CDH infants concluded that the SNAP 2 calculated in the 
first 12 hours of life reliably predicts survival outcomes and the need for ECMO in inborn infants 
with CDH with gestational age > 34 weeks. The SNAP takes only 2–4 minutes to calculate. The 
SNAP 2 score is considered independent of initial ventilation strategy [34].
Some now report the use of the SNAP 2 score with perinatal extension—the SNAPPE. This 
score includes APGARS, birth weight and gestational age, but it is time consuming to calculate. 
The report also includes out‐born infants which is a confounder [35].
Implementation of the SNAP 2 score will provide insight into prognosis and can be used to 
compare severity of illness and evaluate differences in outcomes between centers.
6.3. Permissive hypercapnia and avoidance of lung injury
In the 1990s, the realization that aggressive overventilation causes barotrauma and a worse 
outcome leads to the introduction of minimal ventilation and permissive hypercapnia. This 
approach involves decreased airway pressures to reduce barotrauma, spontaneous respira‐
tion where possible, and acceptance of higher PaCO
2
 and lower pH than previously accepted. 
The introduction of this strategy had the most significant influence on mortality reduction for 
CDH infants over the past three decades [36].
Barotrauma is commonly attributed as the principal cause of death in autopsy studies of CDH 
infants [37].
Complications such as pneumothorax have a detrimental effect on CDH infants. In more than 
one study, all infants with pneumothorax died [38].
The usual limit of permissive hypercapnia in many studies are a PaCO
2
 within the 40s and 
pH of 7.2. The oxygen saturation is kept at 90–95%. Postductal oxygen saturation is correlated 
to other measures of adequate perfusion including lactate, blood pressure, and urine output, 
while maintaining acceptable ventilator parameters.
The next step in management is the introduction of HFOV. Pressure limits range from 12 to 
15 cm H
2
O. The benefit of HFOV has not been completely established. It is often used with 
other management strategies. A trial comparing CMV and HFOV is presently underway [39].
7. Management of PHN
Ensuring good oxygenation is the first step in preventing or treating PHN. The institution of 
effective ventilation is critical. Fluids and inotropes maintain perfusion and should be guided 
by serial echocardiography. When PHN worsens, a cycle of worsening hypoxia and hyper‐
capnia from right to left shunting at both the preductal and postductal levels occurs and sets 
off a vicious cycle of deterioration.
Inhaled nitric oxide (iNO) is a direct pulmonary vasodilator. The inhalation dose ranges 
between 5 and 20 ppm. Although it may reduce the need for ECMO in other newborns without 
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CDH, it has not been shown to reduce the need for ECMO in CDH. Response to NO should be 
confirmed by echocardiography [40].
Sildenafil is a selective cGMP phosphodiesterase inhibitor that can be administered intra‐
venously or as an oral medication. It may enhance inhaled NO‐mediated vasodilation. 
Sildenafil Infusion has been shown to be associated with improved oxygenation in CDH. 
Overall, its use is increasing. Presently, conflicting reports exist as to whether it improves 
outcome or not [41].
Milrinone is a phosphodiesterase 3‐inhibitor and acts to decrease pulmonary vascular resis‐
tance and improve cardiac function. There are few case reports of its efficacy in neonates. 
Although it is widely used, there is no literature that documents an advantageous effect in 
CDH [42, 43].
7.1. ECMO
The most severe CDH cohort fails conventional management and utilizes ECMO for sup‐
port. Infants that undergo ECMO are typically profoundly hypoxemic and acidotic prior to 
and during ECMO cannulation. ECMO benefits infants with reversible lung disease, however 
infants with reversible versus irreversible lung disease can be challenging to identify. Infants 
with reversible lung disease, without CDH, have better documented outcomes. The advan‐
tage of ECMO in CDH infants requires continuous evaluation to resolve the issue of whether 
ECMO actually provides benefit.
A Cochrane review into the randomized controlled trials that investigated the benefits of 
ECMO in neonates concluded the benefit in CDH infants is unclear. The morbidity in those 
that do survive is high and can be costly from complications such as intracranial hemorrhage 
(ICH), bleeding, seizures, or infection. One fifth of infants with CDH that undergo ECMO 
have severe neurodevelopmental problems [42, 43]
The introduction of gentle ventilation strategies, permissive hypercapnia and spontaneous respi‐
ration had a more significant effect on survival than HFOV or ECMO as rescue therapy [35, 39]. 
These strategies increased survival from 50 to nearly 75% for CDH. Standardized postnatal treat‐
ment protocols at ECMO centers is associated with significantly improved survival [44].
7.2. Selection criteria
ECMO is useful if lung disease is reversible. Careful infant selection is critical. Due to the fact 
that the identification of specific CDH infants that will benefit from ECMO is not clear, some 
advocate that all infants with respiratory failure should get ECMO as many with poor prognos‐
ticators have been shown to survive. It is difficult to identify the influence of inadequate lung 
volume (pulmonary hypoplasia) versus reversible pulmonary hypertension in CDH infants 
and the overlap of the two entities. Many infants with CDH will have a honeymoon phase 
where they demonstrate sufficient lung parenchyma for gas exchange prior to clinical deterio‐
ration secondary to pulmonary hypertension. Some authors advocate utilizing clinical parame‐
ters and offering ECMO to any patient who can sustain a preductal oxygen saturation ≥90% for 
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at least 1 hour, a PaO
2
 of 100 on FiO
2
 1.0 and at least one recorded PaCO
2
 < 50 mmHg [45]. CDH 
infants with progressive hypoxemia who meet these initial criteria supported with ECMO have 
85% survival to discharge [46].
7.3. Factors associated with survival
A retrospective review of the CDH Study Group database found that the overall survival for 
CDH infants was 67% and for those requiring ECMO, it was 61%.  Of the infants that required 
ECMO and underwent surgical repair, survivors had greater gestational age (>38 weeks), greater 
birth weight (>3 kg), were less likely to be prenatally diagnosed, less likely to have Apgar <7 at 5 
minutes, less likely to have a patch repair and had shorter ECMO runs of median 9 +/‐ 5 days [47].
7.4. Oxygen index and alveolar‐arterial oxygen gradient (AaDO
2
)
Objective criteria for ECMO patient selection have been suggested in the literature. The two 
most commonly utilized measures are oxygenation index (OI) and alveolar‐arterial oxygen 
gradient (AaDO
2
).
The mortality risk in neonatal respiratory failure can be measured by an OI which is based on 
Pao
2
, and mean airway pressure (MAP).
It is computed by:
  OI =  MAP  ×  FiO 
2
 × 100 /  PaO 
2
 . (1)
In early ECLS studies, OI >40 in three of five postductal arterial blood gas measures 30–60 
minutes apart, a mortality rate > 80% (8, 9) was predicated. Some advance initiation of ECLS 
based on an OI of 25 or greater which has a mortality of 50%. ECMO is considered when respi‐
ratory failure exists and the OI is calculated at between 25 and 40 [39].
Alternatively, AaDO
2
 has also been shown to be sensitive for predicting mortality [48].
  AaDO 
2
  =  ( P 
ATM
 − 47 )   ( FiO 2 ) −  [ ( PaCO 2 )  / 0.8 ] −  PaO 2 (2)
When the OI ≥ 40 or AaDO
2
 > 625 mmHg for 4 hours (or >600 mmHg for 12 hours), ECMO is 
considered mandatory.
7.4.1. Contraindications to ECMO
In addition to unique clinical parameters to assess pulmonary hypoplasia in CDH, there are 
generalized contraindications to neonatal ECMO that correspond to high mortality:
• Prematurity: gestational age <34 weeks (high risk of intracranial hemorrhage) [49]
• A known pre‐ECMO IVH greater than grade 2 [50]
• Weight <2 kg (technical limitation due to cannula size)
• Mechanical ventilation >7–14 days due to risk of fibroproliferative pulmonary disease [51]
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• Hypoxic ischemic encephalopathy [52]
• Chromosomal abnormalities (other than trisomy 21) [53].
7.4.2. Relative contraindications
• Multisystem organ failure or irreversible critical illness [54]
• Evidence of bleeding diathesis/disseminated intravascular coagulation (DIC) (correct prior 
to ECMO) [55]
• Immune compromise [56]
• Seizures prior to ECMO [57]
• Cardiac arrest was previously considered a contraindication but now survival of up to 40% 
after cardiac arrest is reported. The causes of the arrest are variable and the identification 
and treatment of the underlying cause will influence outcome [58]. Of those who survive, 
at least 60% have a reasonable neurologic outcome.
7.4.3. ECMO complications
Complications during ECMO support are associated with worse outcomes. Complications 
increase with prolonged ECMO support.
7.4.3.1. Bleeding:
Bleeding is associated with heparinization. It is the most common complication, occurs in 
10–30% of ECMO runs, and can be devastating [59].
• Intracranial hemorrhage (ICH): ICH is the most common cause of death in newborns on 
ECMO. The etiology is multifactorial. After heparinization, platelet function remains dis‐
rupted for 48 hours after ECMO is discontinued [60]. This effect is increased in infants below 
37 weeks’ gestational age.
• Bleeding at extracranial sites, e.g., gastrointestinal (GI) hemorrhage
• The incidence of bleeding attributed to technical failure is between 2 and 5%. Cannula site bleed‐
ing may be as high as 6%. Cardiac patients requiring ECMO have a higher incidence of bleeding.
In order to decrease the risk of bleeding, the platelet count is kept above 100,000 mm−3. The ACT 
is maintained between 180 and 240 seconds [61]. The occasional discontinuation of heparin may 
be needed.
7.4.3.2. Neurologic
The most serious post‐ECMO morbidities are neurologic. Morbidity and mortality increase 
with greater prematurity. This implies that factors present prior to ECMO are related to neu‐
rologic outcomes. By 2.5–3 years, infants with CDH requiring ECMO had worse neurologic 
outcomes than nonCDH ECMO survivors [62, 63].
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Neonatal seizures are associated with long‐term morbidity and poor outcome including cere‐
bral palsy and epilepsy [42, 43]. Clinical seizures occur in 5–10% of ECMO neonates [64, 65]. 
Abnormal electroencephalogram (EEGs) are predictive of developmental delay. Only 18% of 
ECMO infants with normal EEGs have developmental delays; 35% with one abnormal EEG, and 
58% with two or more abnormal EEGs [66].
Sensorineural hearing loss occurs in 5% of ECMO survivors, though this rate is comparable 
to nonECMO PPHN infants [67].
7.4.3.3. Pneumothorax
Boloker et al. reported 120 consecutive inborn infants managed with a care strategy based on 
permissive hypercapnia, spontaneous respiration, and elective repair [39]. The overall survival 
rate was 75.8%, but, excluding 18 of 120 not treated for lethal anomalies, overwhelming pulmo‐
nary hypoplasia, or prerepair ECMO‐related neurocomplications, 84.4% survived to discharge. 
In this series with excellent outcomes, the need for tube thoracostomy was rare, however, every 
inborn patient (n = 11) requiring a chest tube for pneumothorax died. Generally, the incidence 
of pneumothorax is reported between 4 and 14% and carries a grave prognosis.
7.4.3.4. Mechanical failure
Mechanical failure of the ECMO circuit can occur [65]. Examples included: thrombus in the 
circuit (65%), cannula problems (12%), failure of the oxygenator (6%), pump malfunction 
(2%), and air in circuit (5%). The effect of technical complications on survival is not as great as 
other physiologic complications.
7.4.3.5. Timing of operation
Although surgical management was historically an emergency for infants with CDH, this is no 
longer the approach. Previously, CDH was associated with a poor prognosis and a survival rate 
of approximately 50% with significant morbidity. The aim of medical management in infants 
with CDH is to stabilize for operation. The results of several studies suggest that delayed repair 
of CDH after prolonged stabilization has a beneficial effect on the survival rate. Other authors 
report conflicting results. The optimal time for surgical repair remains controversial and is not 
completely established.
The primary goal of preoperative stabilization is resolution of pulmonary hypertension. 
However, complete resolution of PHN can be challenging. Preliminary experience with the use 
of nitric oxide in infants with CDH has suggested that most infants with hypoxic respiratory 
failure did not show a sustained response.
Almost 500 infants undergoing early (<48 hours) versus delayed (>48 hours) were recently 
compared. The primary outcome was 90‐day survival, and treatment duration (ventilation, 
oxygen, and hospitalization) was the secondary outcome. To adjust for disease severity, 
infants were stratified into three severity groups by Apgar score at 1 minutes (“mild” had an 
Apgar of 8–10, “moderate” 4–7, and :severe” 0–3). Outcomes were compared between early 
repair and delayed repair within each severity group [68].
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Although 90‐day survival was significantly different among the three severities (“mild” 97%, 
“moderate” 89%, and “severe” 76%, p = 0.002), there were no differences in 90‐day survival 
between delayed repair and early repair in each group. In “mild,” there were no differences 
in treatment duration between early and delayed repair. In “moderate,” treatment duration 
was shorter in the early repair group (ventilation 11 vs. 16 days, oxygen 15 vs. 20 days, and 
hospitalization 34 vs. 48 days). In the “severe” group, treatment duration was shorter in the 
early repair group.
The timing of CDH repair appeared to have no influence on 90‐day survival regardless of 
disease severity. Infants in the moderately severe category may benefit from the early repair 
by reducing treatment duration.
Some reports suggest that early repair on ECMO was associated with a decreased time on 
ECMO, decreased complications, and increased survival [69]. Others refute this and report 
increased survival if repair can be delayed until the infant is discontinued from ECMO [70].
Over about one decade (1992–2000), a single institution challenged conventional CDH man‐
agement in the context of a clinical care strategy based on permissive hypercapnia and gentle 
ventilation. All infants underwent a respiratory care strategy based on permissive hypercap‐
nia and spontaneous respiration, combined with elective repair. Arterial blood gas values and 
concomitant ventilator support were recorded.
All CDH infants and the following criteria were retrospectively reviewed: (1) respiratory distress 
requiring mechanical ventilation, (2) in‐born infants, or (3) infants transferred preoperatively 
within hours of birth. Outcome markers such as the need for ECMO, time to discharge to home, 
need for supplemental oxygen at discharge, and the influence of nonECMO ancillary therapies 
(surfactant, nitric oxide, and high‐frequency oscillatory ventilation) were examined.
For 120 consecutive infants with CDH, the overall survival rate was 75.8%. When 18 of 120 
that were not treated were excluded (6 lethal anomalies, 10 overwhelming pulmonary hypo‐
plasia, 3 prerepair ECMO‐related neurocomplications), 84.4% survived to discharge. A total 
of 67/120 were inborn (55.8%). NonECMO ancillary treatments, such as iNO, HFOV, or sur‐
factant, had no impact on the survival rate. ECMO was used in 13.3%. Surgery was transab‐
dominal in all and 7% required a patch. Tube thoracostomy was rarely required, but every 
inborn patient (n = 11) who required a chest tube for pneumothorax died. The overall mean 
settings for respiratory support before surgery in survivors were: PIP: 22, FiO
2
: 43%, PaO
2
: 66 
Torr, PaCO
2
: 41 Torr and Ph: 7.32. Two infants that were successfully discharged on oxygen 
died at 4 and 7 months, respectively and the cause of death was not recorded.
The majority of infants with life‐threatening CDH treated with a care strategy of permissive 
hypercapnia, spontaneous respiration, and elective surgery survive to discharge with mini‐
mal pulmonary morbidity [42, 43].
Overall, the approach of delayed surgery after stabilization is based on clinical evaluation, best 
practices, and retrospective evidence. Delay of operation while waiting for physiologic stabi‐
lization may shift mortality from post‐op to pre‐op in infants that do not survive. The delayed 
operation approach favors better resource utilization and physiologic stress reduction during 
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hemodynamic instability and pulmonary hypertension. The delayed approach also favors 
infant self‐selection as they demonstrate that they can stabilize during the waiting period.
8. Low risk CDH infants
There are few data in lower risk infants to support specific timing of repair of elective CDH 
after hemodynamic stability is achieved. The CDH study group data for low risk CDH infants 
were analyzed. The aim of the analysis was to understand the effect of timing of repair on 
survival in patients who did not require ECMO. Delayed repair did not appear to improve 
survival and if surgery is significantly delayed, there is an incidence of bowel obstruction and 
even volvulus in CDH infants [70].
8.1. Right‐sided CDH
Previously, right‐sided CDH was considered a subgroup of CDH infants with a poor prognosis. 
Twenty‐seven cases of right CDH that presented for prenatal evaluation (MR or fetal echo) or 
postnatal treatment between 1995 and 2002 were retrospectively reviewed. In all cases, the fetal 
liver was herniated into the right chest [71].
The mean gestational age at evaluation was 26.1 weeks. The lung area to head circumference 
ratio (LHR) ranged from 0.32 to 2.5. Associated anomalies were common. There were four 
terminations. Fifty percent of continuing pregnancies had polyhydramnios, premature rup‐
ture of membranes, or preterm labor. The mean gestational age at birth was 36.8 weeks. One 
patient underwent tracheal occlusion at 27 weeks and two died before postnatal repair. The 
overall survival rate was 70% and the postnatal survival rate was 83%. A patch was utilized in 
67% of neonates undergoing surgery. Fifty percent required ECMO with a 75% survival rate. 
Significant morbidity occurred in 53% of survivors and included neurologic sequelae in 32%.
MRI was considered helpful in the determination of liver position and confirmation of the 
diagnosis. This subgroup has a high incidence of preterm complications, comorbidities, and 
a frequent need for ECMO. Close prenatal surveillance and delivery at a tertiary care center 
with ECMO capability is recommended.
In contrast, a more recent series found right CDH was not associated with increased mortality, but 
it was associated with increased requirement for pulmonary vasodilatory therapy and require‐
ment for tracheostomy [72]. However, the conclusion was similar in that the high incidence 
of pulmonary complications indicates an increased severity of pulmonary hypoplasia in right 
CDH and supports a role for delivery in tertiary centers with expertise in CDH management.
9. Repair on ECMO
In contrast to some that recommend delayed operation, others report that, if data are unad‐
justed for severity of disease, delaying CDH repair is associated with increased mortality [70]. 
Congenital Diaphragmatic Hernia
http://dx.doi.org/10.5772/intechopen.69362
169
One multivariate analysis of early versus late repair reports that timing of repair confers no 
difference in outcomes [73]. Most recommend CDH repair should be based on the optimiza‐
tion of clinical parameters as opposed to a specific time period to improve outcome.
Others report that surgical repair on ECMO may confer a slight survival advantage and the 
complications from bleeding may be lessened by the use of tranexamic acid [74]. Others con‐
tradict this recommendation [75]. Similarly, there are significant differences between repaired 
and nonrepaired CDH infants and significant center variation in the rate of nonrepair exists. 
Aggressive surgical management, leading to a low rate of nonrepair, is associated with 
improved risk‐adjusted mortality [76].
An increase in survival to surgery does not always equate to increased survival overall. Some 
authors suggest that if the liver is down, the PHN is less severe, the defect tends to be smaller, 
and the recommended approach is stabilization and delayed repair [76]. For those with the 
liver up, the PHN tends to have increased severity with a larger defect and those may benefit 
from repair on ECMO, but more investigation is needed [77].
9.1. Care strategy for repair of CDH
It is recommended that the operation is delayed until FIO
2
 < 50%, PIP < 25 cm H
2
O, MAP < 12, 
with resolution of pulmonary hypertension by clinical criteria and echo. The infant should have a 
normal acid base balance, stable blood pressure, resolution of anasarca, and almost meet param‐
eters for ECMO discontinuation or have undergone decannulation.
If the infant is on ECMO, consider the use of an AMICAR infusion @20 mg/kg/hour, following 
a loading dose of 100 mg/kg. One must prepare for the large transfusion protocol, and blood 
products should be prepared to allow rapid infusion if needed during operation. The infant 
must have access from anesthesia and surgery and adequate venous and arterial access for 
administration of blood products, medications, and monitoring. Both preductal and postduc‐
tal saturation monitors must be in full view. Blood gases will be monitored at baseline and 
then approximately every 30 minutes during the operation. Extensive team communication 
between anesthesia, surgery, and neonatology is imperative during the CDH repair operation.
9.2. Outcomes and long‐term follow‐up
The improvement in ventilation and resuscitation modalities in recent years has improved 
survival in CDH infants. The increased survival led to an increase in the long‐term morbidity 
burden. As more survivors are advancing in years, our understanding of the complexity of 
the CDH pathology has improved [78, 79].
The CDH patient is a complicated patient with an intricate disease course. Follow‐up should 
be composed of a multifaceted approach as there are surgical and nonsurgical consequences 
to the disease process.
9.3. Hernia recurrence
Recurrence of the diaphragmatic hernia has been reported in 8–50% of CDH survivors. The 
size and the type of repair (patch vs. primary closure and thoracoscopic vs. open repair) 
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appear to be the most commonly reported factors affecting recurrence [80–84]. Survivors with 
large defects or who underwent patch or laparoscopic repair tend to be more prone to have 
a recurrence. Recurrence can occur months to years from the initial repair. Recurrences can 
present with a spectrum of findings from the asymptomatic patient to a patient with bowel 
obstruction.
9.4. Thoracoscopic versus open repair
Conflicting studies exist regarding the hernia recurrence rate after thoracoscopic or open 
repair for infants with CDH. Many studies report an increased incidence of recurrence after 
thoracoscopic repair. In general, these are poorly controlled, retrospective studies. It has been 
difficult to determine if the increased recurrence is secondary to patient selection, techni‐
cal variations in repair, experience of the surgeon, or a combination of all of the above. The 
International Pediatric Endoscopic Group (IPEG) reported one of the first multiinstitutional 
studies across seven tertiary care pediatric hospitals and attempted to address these questions. 
IPEG attempted to specifically evaluate the technical variations of thoracoscopic repair of CDH 
to identify if certain methods are associated with recurrence [85].
They compared primary versus patch repair, type of patch and suture utilized, technique of 
patch application, and use of extracorporeal/rib fixation sutures. The study concluded there 
was no statistically significant technical factor related to recurrence to currently recommend 
a standardized surgical approach to thoracoscopic repair [85].
9.5. Pulmonary outcomes
CDH survivors are more prone to experience a pulmonary morbidity. Around 25% of CDH sur‐
vivors develop an obstructive airways disease [86, 87]. An estimated 55% of survivors develop 
recurrent respiratory infections regardless of their chronic pulmonary or airway morbidity [88]. 
Pulmonary hypertension can also persist and correlates with early mortality [89].
9.5.1. Neurological and developmental outcome
Longitudinal neurodevelopmental and neuroimaging studies of CDH survivors have demon‐
strated the survivors’ susceptibility to neurodevelopmental delay. Magnetic resonance studies 
revealed anatomic abnormalities in 17% of CDH patients [90]. Delayed brain maturation appears 
to be prevalent, especially in infants with severe CDH [91]. Such findings correlate with future 
cognitive impairment. The findings correlated with ECMO treatment, right‐sided CDH, intra‐
thoracic liver, patch repair, and prolonged oxygen use after multivariate analysis [67].
Sensorineural hearing loss, independent of ECMO use, has been described in CDH survivors 
[92, 93] and is believed to stem in part as a side effect of treatment. Approximately 35% of 
survivors will require hearing aids [94, 95].
9.5.2. Nutritional, growth, and gastrointestinal outcomes
Failure to thrive has been well documented in CDH survivors, with estimates of between 20 
and 50% of survivors experienced growth retardation and remains in the lower percentiles 
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on the growth chart [96, 97] and it is believe to be a result of complex processes including oral 
aversion, GERD, increased metabolic stress due to ingoing morbidity. Around 33% of survi‐
vors require some form of tube feeding [80, 98].
Gastroesophageal dysmotility and regurgitation has been found to be prevalent in CDH survi‐
vors with a prevalence of between 45 and 90% reported [97–101]. The tendency to GERD may 
contribute to the survivor’s failure to thrive. However, at present, there is no evidence that 
routine fundoplication is needed.
9.5.3. Musculoskeletal outcomes
Chest wall deformities and scoliosis have been reported in CDH survivors. The litera‐
ture estimates the prevalence of chest wall deformities to be approximately 16–48% [86, 
102–105]. While thoracic scoliosis has been reported in 10–27% of survivors [82, 105]. 
Though prevalent, not all deformities will require intervention. The prevalence of scoliosis 
has been found to be more prevalent in survivors with big defects who underwent patch 
repairs [84, 105].
9.5.4. Other outcomes
In addition to the above‐mentioned long‐term morbidities, associated congenital defects have 
been reported in around 33–40% of CDH infants [106–112]. Associated congenital anomalies 
such as cardiac defects, genitourinary abnormalities, and neurological anomalies should be 
taken into consideration when planning long‐term follow‐up.
9.5.5. Follow‐up
The complexity of the CDH patient mandates a structured multidisciplinary follow‐up. 
In 2008, the American Academy of Pediatrics published an outline for the follow up of the 
patient with CDH [107]. This was done to identify and treat morbidities to prevent any further 
disability. The outline is summarized in Table 1 [107].
Before 
discharge
1–3 months 
after birth
4–6 months 
after birth
9–12 months 
after birth
15–18 months 
after birth
Annual 
through 16 
years
Weight, length, 
occipital‐frontal 
circumference
X X X X X X
Chest radiograph X If patched If patched If patched If patched If patched
Pulmonary function 
testing
If indicated If indicated If indicated
Childhood 
immunizations
As 
indicated 
throughout 
childhood
X X X X X
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Before 
discharge
1–3 months 
after birth
4–6 months 
after birth
9–12 months 
after birth
15–18 months 
after birth
Annual 
through 16 
years
RSV prophylaxis RSV season 
during first 
2 years after 
birth (if 
evidence 
of chronic 
lung 
disease)
X X X X X
Echocardiogram and 
cardiology follow‐up
X If previously 
abnormal 
or if on 
supplemental 
oxygen
If previously 
abnormal 
or if on 
supplemental 
oxygen
If previously 
abnormal 
or if on 
supplemental 
oxygen
If previously 
abnormal 
or if on 
supplemental 
oxygen
If previously 
abnormal 
or if on 
supplemental 
oxygen
Head computed 
tomography or MRI
If (1) 
abnormal 
finding 
on head 
ultrasound; 
(2) seizures/
abnormal 
neurologic 
findingsa; or 
(3) ECMO 
or patch 
repair
As indicated As indicated As indicated As indicated As indicated
Hearing  
evaluation 44
Auditory 
brainstem 
evoked 
response or 
otoacoustic 
emissions 
screen
X X X X Every 6 
months to 
age 3 years, 
then annually 
to age 5 years
Developmental 
screening evaluation
X X X X Annually to 
age 5 years
Neurodevelopmental 
evaluation
X X Annually to 
age 5 years
Assessment for oral 
feeding problems
X X If oral 
feeding 
problems
If oral feeding 
problems
If oral feeding 
problems
If oral 
feeding 
problems
Upper 
gastrointestinal 
study, pH probe, 
and/or gastric 
scintiscan
Consider 
for all 
patients
If symptoms If symptoms Consider for all 
patients
If symptoms If symptoms
Esophagoscopy If symptoms If symptoms If symptoms 
or if abnormal 
gastrointestinal 
evaluations
If symptoms If symptoms
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10. Conclusions
The management of congenital diaphragmatic hernia remains a challenge. Mortality is dependent 
on associated malformations, the severity of pulmonary hypoplasia, pulmonary hypertension, 
and iatrogenic lung injury associated with aggressive mechanical ventilation. A comparison of 
the mortality rate of CDH infants in a single center between 1995 and 2005 versus 2006 and 2016 
revealed that the mortality rate significantly decreased in the later time period, 17.9 compared to 
4.4%. Prenatal diagnosis, intrathoracic liver, low Apgar score, and low birth weight were defined 
as independent risk factors for mortality. The mortality in ECMO‐treated patients was 50% in 
both time periods [113]. Despite no significant differences in the incidence of independent risk 
factors and the use of ECMO between the two time periods, mortality decreased over time.
Therefore, there are many important factors involved in a successful outcome after CDH 
repair. Large multicenter studies are necessary to define those critical factors and to deter‐
mine optimal treatment strategies.
Infants with CDH should be delivered as close to term as possible. At birth, management 
includes bowel decompression, avoidance of mask ventilation, and endotracheal tube place‐
ment if required. The care strategy includes gentle ventilation, hemodynamic monitoring, 
and treatment of pulmonary hypertension followed by surgery. Although inhaled nitric oxide 
is not Food and Drug Administration (FDA) approved for the treatment of pulmonary hyper‐
tension in CDH infants, it is commonly used. Extracorporeal membrane oxygenation (ECMO) 
is considered if conventional medical management fails for infants ≥  34 weeks’ gestation or 
with weight >2 kg and no associated major lethal anomalies. With advances in CDH manage‐
ment, the overall survival has improved and has been reported between 70 and 90% in non‐
ECMO infants and up to 50% in infants who undergo ECMO.
There are many important areas of research that may promote better understanding of the 
development of CDH. Fujinaga et al. reported that cord blood endothelial progenitor cells are 
Before 
discharge
1–3 months 
after birth
4–6 months 
after birth
9–12 months 
after birth
15–18 months 
after birth
Annual 
through 16 
years
Scoliosis and chest 
wall deformity 
screening (physical 
examination, chest 
radiograph, and/
or computed 
tomography of the 
chest)
X X
Notes: The neurosensory tests performed and frequency of surveillance may differ among infants with CDH because of 
variability in neurologic, developmental, and physiologic impairments. Follow‐up should be tailored to each infant. RSV 
indicates respiratory syncytial virus.
a Muscle weakness, hypotonia, hypertonia, or other abnormal neurologic sign or symptom.
Table 1. Recommended schedule of follow‐up for infants with CDH [107].
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altered in CDH infants, but the mechanism is unknown [114]. Russo et al. reported the use of 
transplacental sildenafil rescues lung abnormalities in a rabbit model of CDH, improves vas‐
cular branching, and reduces pulmonary vascular resistance [115]. This promising research 
may further alter and improve outcomes for infants with CDH.
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